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ABSTRACT
The application of plasmonicenhanced Raman imaging of
cancer cells and drug delivery
is gaining momentum. Here, we
propose a new theranostic
strategy based on an efficient
plasmonic-tunable
Raman/Fourier
transform
infrared (FTIR) spectroscopy
imaging, to simultaneously
evaluate the anticancer drug
scattering cellular imaging and
the Raman scattering molecular
vibration signals in living cells. This technique allows to monitoring the drug release
throughout the cell cycle and in vivo biodistribution and biocompatibility with low dose drug
therapy (200 µg/mL) and low toxicity effect. This system can directly track in real-time the
delivery and release of an anticancer drug (mitoxantrone, MTX) from gold nanostars in single
1

BIOMATERIALS
living cells and in mice (healthy and lung cancer mice models), revealing a strong
accumulation in the heart of healthy mice 5 minutes after administration and infiltration in the
tumor site of lung cancer mice 5 hours after systemic injection. This in vivo SERS detection
method holds a great promise for application in image-guided cancer chemotherapy or as a
nonspecific anti-inflammatory therapy for patients with cardiovascular diseases or chronic
heart failure.

D

rug delivery systems using nanomaterials have been widely used to improve
drug efficiency, reducing the dosage and minimizing side effects.1,2 However,
not every drug can be successfully conjugated, tracked and delivered into target

organism. For example, pharmacokinetic analyses of nanoparticles conjugated with an
anticancer drug such as doxorubicin do not give information about the position, area, and
size of drugs within tissue due to cell toxicity and its fluorescence wavelength overlaps with
the tissue. 12 Owing to their biocompatibility, feasible surface modification and tiny size, gold
nanoparticles (GNPs) have been used for drug delivery, tumor targeting, gene therapy and
photothermal therapy.5-11 However, Raman signals are inherently weak for in vivo imaging
and drug location tracking. GNPs can provide broad wavelength for Raman scattering. Since
it is a challenge to avoid auto-fluorescence and minimize light absorption from tissue, one
way to amplify weak Raman signals is to employ Surface-enhanced Raman spectroscopy
(SERS) using sharp ending metal surfaces, such as nanostars.5 As a result of utilizing different
shape plasmonic-enhanced Raman signal from anticancer drugs, it has been possible to obtain
a real-time cellular imaging of cancer cells.
Recently, our group has developed a protocol to synthesize gold nanostars to enhance the
Raman signal using SERS.13 We found that it is necessary to optimize several conditions and
physical properties of nanostars to visualize anticancer drugs inside cancer cells and organs.
By optimizing these conditions gold nanostars can tune the wavelength of gold nanospheres
from 560nm to the range between ultraviolet and infrared regions.14,15 For example, Hirsch et
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al. have employed nanoshells to tune a wavelength of gold nanoparticles at 720 nm to achieve
photothermal ablation of tumor cells by irradiation using near-infrared laser light in vivo.16
Gold nanostars, star-shaped gold nanoparticles, have exceptional optical properties.17-20 They
display two surface plasmon bands consistent to the transverse and longitudinal surface
plasmon bands in the visible (520 nm) and the near-infrared regions, respectively15 Thus, gold
nanostars are special materials with an intense surface plasmon band that affords absorption,
fluorescence21-23 and light scattering24,25 in the near-infrared region, inducing two-photon
luminescence phenomena.26
Hexadecyltrimethylammonium bromide (CTAB) is a common material for gold nanostar
synthesis. CTAB provides a cationic detergent to stabilizing agent during the preparation of
gold nanostars.27 The disadvantage of using CTAB method, the toxicity is not only come from
CTAB, but also from silver ions.28 Reducing concentration of CTAB during synthesis will
cause the aggregation of nanostar. HEPES buffers (3-[4-(2-hydroxyethyl)piperazine-1yl]propane-1-sulphonic acid) have been used commonly used in cell culture and work as a
functional reducing agent to directly change the shape of spherical gold nanoparticles to star
shape.29 Using this method we were able to produce three-dimensional branched gold
nanostars and drug-nanostars.
In the present work, we proposed a new theranostics strategy using Raman/FTIR imaging
spectroscopy to track in real-time the delivery and release of an anticancer drug from
nanostars in living cells and their biodistribution in vivo. Mitoxantrone (MTX)12 was
conjugated to the surface of gold nanostars via a thiolated and carboxylated poly(ethylene
glycol) (PEG) spacer that was attached by one-step ligand exchange and that provided the
anchoring moieties for the covalent binding of amine-containing molecules like the MTX
through carbodiimide chemistry (EDC/NHS coupling). MTX is a hydrophobic drug, slightly
soluble in water, but with a high solubility in lipids as previously demonstrated.30 With a
lipid/water partitioning coefficient of around 230,000, it is rational to undertake that MTX
3
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crosses the plasma membrane at a high rate.31 The MTX is an anticancer drug with significant
clinical

activity.

Furthermore,

MTX

has

antiviral,

antibacterial,

antiprotozoal,

immunomodulating, and antineoplastic properties and is mutagenic in some animal systems.32
Moreover, MTX has a red fluorescence emission as well as a strong Raman scattering signal
with gold nanoparticles. The Raman signals of MTX molecules were evaluated by the
plasmonic field of GNPs, depending on the distance between the drug molecules and the
nanoparticle’s surface. This technique allowed the simultaneous detection of the anticancer
drug scattering cellular imaging and the biomolecules in living cells and in two mice models 
heart tissue imaging and drug accumulation in healthy mice and tumor imaging in a lung
cancer mice model (see Figure 1). Therefore, gold nanostars can be used as a theranostic
platform for efficient intracellular and in vivo SERS detection combined with real-time drug
delivery using Raman/FTIR imaging, especially for image-guided cancer chemotherapy or
other diseases.

4
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Figure 1. Gold Nanostars for theranostics: intracellular and in vivo SERS detection
combined with real-time drug delivery using plasmonic-tunable Raman/FTIR imaging.
This system can directly track in real-time the delivery and release of an anticancer drug
(mitoxantrone - MTX) from gold nanostars in single living cells and in mice (healthy and lung
cancer mice models). This in vivo SERS detection method holds a great promise for
application in image-guided cancer chemotherapy or as a nonspecific anti-inflammatory
therapy for patients with cardiovascular diseases or chronic heart failure.

RESULTS AND DISCUSSION
The application of plasmonic-enhanced Raman signal from an anticancer drug conjugated to
gold nanostars in real-time imaging of cancer cells and drug delivery is gaining momentum.12
In order to enhance pharmacokinetic analyses of nanoparticles conjugated with an anticancer
drug, gold nanostars were employed in the current study.
5
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The gold nanostars were synthesized via seed mediated route using HEPES buffer and
conjugated with a thiolated and carboxylated poly(ethylene glycol) (PEG) spacer that
provided the functional groups for the covalent binding of amine-containing MTX (2 amine
groups) through carbodiimide chemistry (EDC/NHS coupling) (Figure 2A). See supporting
information for detailed description about the functionalization and quantification of PEG and
MTX on the surface of the nanostars (Supporting Information Figures S1-S2 and Table S1).
Briefly, The final PEG:Nanostar molar ratio was around 600:1 and the MTX:Nanostar was
100:1 (see Table S1, Supporting Information).
Electron microscopy was employed to confirm the change in the dynamic light scattering
profile of the nanospheres. Figure 2B shows electron microscopy images of 10 nm gold
nanospheres used as seeds for the synthesis of gold nanostars. The synthesized nanostars
presented a central core and six vertices in a three-dimensional arrangement, with an average
diameter of approximately 35 nm (Figure 2C).

6
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Figure 2. (A) Synthesis of gold nanostars via seed mediated route using HEPES buffer. Gold
nanostars were prepared by reducing Au3+ using 10 nm citrate capped gold nanospheres as
seeds in HEPES (3-[4-(2-hydroxyethyl)piperazine-1-yl]propane-1-sulphonic acid) buffer,
where HEPES is serving as both reducing and shape-directing agent. Then, nanostars
were functionalized with thiolated(-SH) PEG by ligand-exchange  between the thiold
groups and the citrate groups on the nanoparticles; and Mitoxantrone (MTX) by EDC/NHS
coupling . Scanning Electron microscopy (SEM) images of nanosphere (B) and nanostars
(C) functionalized with MTX. UV-vis spectra of the same gold nanospheres (D) and
7

BIOMATERIALS
nanostars (E) in aqueous solutions. The extinction coefficient of nanostars is 6×108 M−1.cm−1.
Scale bars, 100 nm.

The optical properties of the GNPs in suspension thus reflect the characteristics of the local
fields associated with the surface plasmon resonance (SPR). The UV-Vis spectra of the gold
nanospheres modified with MTX (MTX:Nanosphere molar ratio of approximately 45:1) show
a typical SPR peak of around 528 nm, consistent with a 10 nm GNP functionalized with MTX
(Figure 2D). Besides aggregation, changes in surface charge, size, and morphology of
particles are responsible for this change in SPR. In fact, nanospheres and nanostars were
compared in terms of size and charge, revealing that nanospheres showed an average diameter
of 15.5 ± 3.1 nm as measured by dynamic light scattering (DLS) and negative charge (zeta
potential −20.2 ± 2.5 mV), whereas the nanostars revealed a mean particle diameter of 35.6 ±
3.6 nm and a negative charge (zeta potential −24.3 ± 1.8 mV).
More importantly, the stability of the gold nanostars solution with and without MTX
functionalization was tested and remained stable up to one month in 4ºC. The hydrodynamic
particle size and zeta potentials of the nanostars, as well as their SPR peaks were measured
during 30 days (Table 1). As shown in Table 1, the size, charge and surface plasmon peaks
remain stable for days with no significant changes over time. The stability of the MTXnanostars was also evaluated in the presence of increasing amounts of serum overtime with no
significant effect on the MTX release from the nanostars for up to 30 days (Supporting
Information Figure S3).
Table 1. Physico-chemical characteristics of Nanostars and Nanostars+MTX for 30 days.

NANOSTARS

Time
Day 1
Day 2
Day 3
Day 4
Day 5
Day 10
Day 15

Hydrodynamic
Diameter (nm)
35.5±2.3
35.5±3.3
35.1±3.4
35.7±21
35.4±2.8
37.2±3.0
35.8±3.7

Zeta
Potential (mv)
-19.1±2.1
-21.2±1.8
-22.3±2.1
-25.7±1.9
-22.2±1.7
-25.9±1.5
-25.1±1.5
8

(nm)

(nm)

601±9
602±11
599±15
601±17
602±12
601±18
601±17

729±11
732±11
733±13
729±15
728±13
730±14
733±21

NANOSTARS + MTX
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Day 20
Day 25
Day 30
Day 1
Day 2
Day 3
Day 4
Day 5
Day 10
Day 15
Day 20
Day 25
Day 30

35.5±3.2
38.1±3.4
37.7±3.2
38.2±1.3
38.1±3.6
38.5±4.4
39.0±3.5
38.1±1.8
38.2±6.0
38.7±4.9
38.5±3.6
39.2±2.5
38.6±2.7

-25.2±1.7
-25.5±2.2
-22.5±2.1
-23.2±1.5
-21.8±2.8
-23.2±2.4
-24.1±2.0
-23.5±2.1
-24.8±1.5
-24.3±2.8
-23.5±1.9
-23.9±2.4
-24.5±1.6

603±21
598±17
601±12
605±5
606±10
602±4
602±7
603±11
601±8
606±14
604±8
610±2
605±10

729±17
733±12
730±15
732±5
735±9
731±8
732±11
730±14
732±7
733±15
732±7
736±13
735±11

Regarding the optical properties of the GNPs, drug-loaded gold nanostars showed two SPR
peaks: a transverse plasmonic resonance peak at 600 nm, confirming the presence of a
spherical core, and a longitudinal plasmonic resonance peak at 730 nm, confirming the
presence of the branch-shaped aggregation around the spherical core (Figure 2E). The peak at
600 nm attributes from the spherical core and the peak at 730 nm attributes the peripheral
vertices. The spherical core of nanostar results in a SPR similar to the nanospheres while the
multiple vertices contribute SPR in the near infrared range.33,34
The Raman spectra of the MTX-loaded gold nanostars under different laser lines (532, 633
and 785 nm) were also analyzed (Figure 3A). Since the intensity of the returned Raman
signal is inversely proportional to the fourth power of the excitation wavelength, shorter
wavelengths like 532 nm can provide stronger Raman scattering; however, can also cause
sample fluorescence, which may interfere with Raman signal. As local field hotspots, the
sharp vertices nanostars under a near infrared excitation source can eliminate sample
fluorescence from most organic molecules Therefore, the best signal-to-noise ratio (SNR) for
the MTX gold nanostar was observed for the laser line at 785 nm, as it largely avoids
fluorescence but still returns a Raman signal sufficient to enable detection at a good SNR.
A stronger signal from MTX-nanostars inside the cells was observed when compared to the
signal in the extracellular medium (Figure 3B). The signal is higher inside the cells once the
9
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gold nanostars are already abundant in the intracellular medium, changing the electric field
distribution being the highest intensity located inside of the cell. This is a consequence of the
cell containing gold nanostars acting as a focusing medium and the largest enhancement is
located inside the cell. Even though different laser excitations can be in resonance inside or
outside the cell, the intracellular medium containing the gold nanostars can change the spatial
location of the maximum electric field providing selective amplification inside the cell. This
represents a significant difference in terms of Raman spectroscopy due to the non-linear
relation between Raman intensity and electric field.35 As shown in Figure 3B, Raman
scattering was not observable under the measurement conditions employed in the presence of
drug-loaded gold nanostars outside the cells at a source wavelength of 785 nm. For the MTXnanostars inside the cells, three different groups of modes were observable, associated with
aromatic C–C stretching at 460 and 1300 cm-1 of the MTX. The vibrational modes observed in
the SERS spectra (Figure 3B) are assigned to the corresponding vibrational modes, in
accordance with the observations of SERS of the MTX on the surface of the gold nanostars.
Consistent with literature,36 two Raman bands with strong scattering intensities are observed
at 460 and 1300 cm-1. Ganbold et al. also show that MTX spherical GNPs present two surface
plasmon bands corresponding to the transverse and longitudinal Raman scattering bands in
the visible (520 nm) and the near-infrared regions, respectively.36 The authors also performed
Raman measurements to identify whether MTX spherical GNPs are inside the cell, using
characteristic vibrational bands of the drug molecules. However, MTX on spherical GNPs
appeared to exhibit strong Raman intensities upon excitation at 633 nm through a resonanceenhancement process, whereas our MTX nanostars present the best SNR at 785 nm. The
aggregate spheres can cause a longitudinal band at 633 nm, but the multiple vertices of the
nanostars contribute SPR in the near infrared range.
These data prove that MTX-nanostars are optimal candidates for intracellular SERS detection
and drug release using Raman/FTIR imaging and that behave as Raman scattering enhancers
10
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due to their tunable SPR and large number of hot spots on the surface associated sharp tips.
The results are consistent with the requirement for enhanced electric fields at hotspots
associated with the vertices of star shaped nanoparticles.13,37 Thus, gold nanostars are unique
materials with an intense surface plasmon band that affords absorption in the near-infrared
region.21-26

Figure 3. (A) SERS response of the gold nanostars under different laser lines (532, 633 and
785 nm). (B) SERS signal inside and outside cell. The red line indicates the SERS signal of
MTX-nanostars inside cell. The blue line shows the Raman spectrum of the MTX-nanostars
outside the cells.
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To evaluate cellular uptake and biodistribution within cellular components and organelles,
ultrastructural TEM images of human Caucasian lung epidermoid carcinoma cell (Calu-1
cells) further revealed that the MTX-nanostars were taken up by these cells in a larger
extension than the bare nanostars, and were mainly localized in intracellular organelles
(Figure 4A-B). After 24 hours of incubation, MTX-nanostars were found in the cytoplasm,
clustered or monodispersed, demonstrating their capability to cross biological membranes and
shuttle the MTX drug into the cytoplasm (Figure 4B).
Concerning biocompatibility, MTX-nanostars exhibited a reduced survival rate compared to
nanostars alone. In a previous study, different shaped gold nanoparticles, such as spherical,
triangular and hexagonal shaped have been investigated upon the cell survival rate of Calu-3
epithelial cells. The cytotoxicity was only observed after 72 hours following exposure of up to
1 mg/mL. In the current study, no significant (p>0.05) changes in cell viability were observed
for either particle compared to the negative control at all concentrations tested (Figure 4C). In
contrast, a significant (p<0.05) loss in human Caucasian lung epidermoid carcinoma cell
(Calu-1 cells) viability was found following exposure to MTX-nanostar (50% viable) for 72
hours at 1 mg/mL (Figure 4C), when compared to negative control levels. Noticeably, Calu-1
cells remained viable for both types of particles and concentrations of up to 0.2 mg/mL after
72 hours (Figure 4D). Further to the findings at 1 mg/mL, the loss in cell viability observed
after MTX-nanostar exposure was found to be significantly different (p<0.01) to the status of
the Calu-1 cells after exposure to the nanostar (Figure 4C). A concentration of 200 µg/mL
MTX-nanostars was used for further in vivo studies. These findings clearly show that
nanostars, in contrast to nanostar-MTX, elicited only limited, if not negligible cytotoxicity,
whilst nanostar-MTX, at least at doses exceeding 200 µg/mL, significantly affected cell
viability.
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Figure 4. Nanostars cellular uptake and cytotoxicity in human Caucasian lung
epidermoid carcinoma (Calu-1 cells). Ultrastructural TEM images of Calu-1 cells incubated
with 200 µg/mL of nanostars (A) and MTX-nanostars (B) for 24 hours. Scale bars: A) 2 μm
and B) 5 μm. (C) Percentage of cell viability after 72 hours’ exposure to increasing
concentration of nanostars with and without MTX, when comparison with only cells. MTXnanostars cause cell viability to drop more than 50%. (D) A similar trend was also noted for
cell viability with increasing incubation times from 6 to 72 hours, using 0.2 mg/ml of
nanostars with and without MTX. Data shown is the mean ± standard error of the mean (n=3).

In order to evaluate and characterize intracellular SERS detection and drug release, real-time
Raman/FTIR and SERS maps were recorded for cells (human adenocarcinoma Calu-1 cells)
with MTX-nanostars during 48 hours of incubation using the Perkin Elmer Spotlight 400
system for the FTIR and the LabRAM HR Evolution spectrometer for the SERS maps.
Representative unprocessed FTIR and SERS maps, generated by the Spectrum image
software, show spectrally averaged absorbance recorded from samples (Figure 5A), for
13
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several time points (1, 8 and 48 hours). This allows to detect the modification of the
wavelength of laser resulting in a fingerprint of information on the drug structure release.
Nanoparticle regions are well defined in both the FTIR and SERS maps, due to their varying
density and thickness. Spectra of the cells at 1, 8 and 48 hours of exposure to MTX-nanostars
were extracted from the FTIR and SERS maps, evaluating the spectra of cellular structures
characteristic of the cell line (see Figure 5B). Each spectrum was calculated as an average of
30-40 signals extracted from the FTIR and SERS maps characteristic of the defined cellular
structure and was subjected to pre-processing using the RMieS-EMSC algorithm.38 The
RMieS-EMSC algorithm is used to correct the infrared spectra and remove spectral
distortions from Resonant Mie Scattering of biological cells.

14
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Figure 5. Real time monitory of MTX-Nanostars under FTIR and confocal microscopy
imaging. (A) Real-time absorbance FTIR and SERS maps on Human Caucasian lung
epidermoid carcinoma cells (Calu-1 cells) incubated with drug gold nanostars during 48 hours.
Red color represents region of a nanoparticle, green and light blue indicate the background.
Scale bars, 20 µm. (B) FTIR (on the left) and SERS (on the right) spectra of cells incubated
with drug gold nanostars for 1, 8 and 48 hours. (C) MTX-Nanostars under confocal
microscopy from 24 to 72 hours of incubation. Scale bars, 20 µm.

The MTX-nanostars were observed under confocal microscopy from 24 h to 72 h (Figure 5C).
The red color fluorescent dots (from MTX, emission maximum at 596 nm, see Figure S2)
indicated the MTX-nanostars spreading in cytoplasm. The amount of MTX released was
estimated by both the increase in FTIR signal and the fluorescence intensity. Both FTIR and
15
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fluorescence intensity provide quantitative relationships between the spectral intensities of
MTX concentrations in cells.
For in vivo SERS detection in healthy mice, live images of C57BL/6 mice were acquired from
1 to 5 minutes after IV injection of MTX-nanostars (200 µg/mL), showing a massive
accumulation in the heart (Figure 6A). Ex vivo images of the heart at 5 min after IV injection
are depicted in Figure 6B. This happens due to the presence of a highly organized vascular
structure in the heart, favoring the accumulation of anticancer drugs within normal tissues
over time, with a greater exposure to most normal tissues, such as heart. Indeed, Patel et al.
has also reported that the distribution of anticancer drugs such as doxorubicin, mitoxantrone
and topotecan from blood vessels is better in normal tissues, such as the heart and liver
compared to the distribution in solid tumors.12 In fact, the biodistribution of MTX-nanostars
was also confirmed by ex vivo organ inductively coupled plasma mass spectrometry (ICPMS) for 1 and 5 minutes after injection of the nanostars. The results show that 5 minutes after
injection, MTX-nanostars are almost exclusively accumulated in the heart (consistent with the
in vivo images in Figure 6A), with no significant accumulation in most of the other tissues
and organs (Supporting Information Figure S4A). Kreyling et al. also show that
nanoparticles distribute into heart at the first blood circulation and start to aggregate into lung
after 4 hours.39 Our results also supports this idea that drugs are distributed in the blood,
which is likely to provide greater access to well perfused organs such as the heart, liver and
lung.
Average absorbance FTIR maps also showed evidence of hotspots due to the high intensity of
MTX-nanostars on the heart tissue (Figure 6C). The color red represents region of the
nanoparticle, green and light blue were the background. Hematoxylin and eosin (H&E)
staining on heart tissue was shown in bright field image (Figure 6D) in accordance with the
FTIR maps (Figure 6C). The H&E staining image can only show heart histological structure,
but it is not sufficient for imaging of nanoparticles or small aggregates and not specific to
16
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anticancer agents.40 FTIR imaging does not require fixation, sectioning and staining as in
Figure 6C and the multiple vertices nanostars have the capability to enhance the MTX signal
at the infrared range. FTIR maps can clearly provide the location and density of MTXnanostars in heart tissue at the same magnification view. Consequently, the experimental
setting can reduce laboratory operations and maintenance costs.

Figure 6. In vivo and ex vivo images of MTX-Nanostars in a healthy mice model. (A) In
vivo live images of mice (n=6 animals) 1 min to 5 min after IV injection of MTX-Nanostars.
17

BIOMATERIALS
(B) Ex vivo heart at 5 min after IV injection. (C) Average absorbance FTIR maps on heart
tissue. Red color represents region of nanoparticle, green and light blue indicate background.
(D) H&E staining representing of heart tissue from the same sample provided in (C). Scale
bars, 200 µm. (E) Representative confocal microscopy images of heart, aorta and skin tissue
immunostaining from sham (no nanostars treatment) and MTX-nanostars treated groups,
showing the biodistribution and accumulation of MTX-Nanostars in heart and aorta
endothelium. Red color represents region of a MTX-Nanostars, green color shows actin
staining.

In order to confirm the biodistribution of MTX-nanostars into the heart of healthy mice,
immunocolocalization staining was performed (Figure 6E). The punctuated red color was
represented the region of MTX-nanostars at laser line 514 nm, the green color was shown the
actin structure of endocardium and myocardium at laser line 488 nm. No red color signal in
the tissue of the control animal without MTX-nanostars was observed. The MTX-nanostars
were located in among the green actin structure of the heart and aorta tissue (Figure 6E). The
heart tissue and aorta tissue are permeable to MTX-nanostars due to high pressure of blood
stream. Representative confocal microscopy images of heart, aorta and skin tissue confirm
that the MTX-nanostars can cross the endothelial membrane in the aorta and heart. Moreover,
no MTX-nanostars fluorescent signal was present on the skin located on the back of mice with
the highest fluorescent intensity point under NIR imaging (no red color signal was located on
the skin area, Figure 6E). The fluorescent signal on the back of the mice can be seen in
Figure 6A. This data further provides evidence that MTX-nanostars biodistribution in heart
and aorta is attributed to the fluorescent signal on the back side of mice (Figure 6A).
The biodistribution and accumulation in the heart is likely to be more efficient due to a highly
organized vascular structure and large pressure gradients across the endothelial membrane.12
These results confirm this method as a great promise for application as a nonspecific antiinflammatory therapy for patients with cardiovascular diseases or chronic heart failure. In fact,
MTX has also been used with success as a nonspecific anti-inflammatory therapy for patients
with cardiovascular diseases or chronic heart failure.41
18

BIOMATERIALS
Concerning the in vivo SERS detection in a lung cancer mice model, we were able to image
the characteristic SERS peaks and signal accumulated on the lung tumors of mice treated with
MTX nanostars. The C57BL/6 mice bearing human Calu-1 xenograft lung tumor (3-mm
diameter) received 0.2 mL (200 µg/mL) of MTX nanostars. The MTX nanostars were
administered in a single injection via tail vein. SERS spectra were taken 5 hours after
injection. SERS measurements from the tumor tissue revealed the presence of MTX-nanostars
(Figure 7). In order to test the development of the lung tumor in mice, bioluminescence
imaging was carried out to serially assess lung tumor in each mouse treated with MTXnanostars, with luciferase activity as a measure for tumor burden (Figure 7A).
In order to track MTX-nanostars in tumor and lung tissues plasmonic-tunable Raman/FITR
imaging spectroscopy was used (Figure 7B). The cancer tissue was under processed with
standard cryosection steps using regular histology methodologies. The sections were cut and
spread on 2 mm CaF2 substrate, without any chemical treatment, in order to prevent any
further chemical modification. Figure 7B shows the FTIR image of MTX-nanostars
accumulated on lung tissue, revealing several tumoral clones in the lung. With this method we
are able to image each individualized tumor in the lungs (arrows in Figure 7B). Imaging the
lung tissue at different time points revealed that MTX-nanostars are uniformly distributed
inside lung tissue and tumor at 5 hours after administration (Figure 7D), whereas ate 0.5
hours is still mainly around the tumor microenvironment (Figure 7C).
This experiment confirms the SERS signal in vivo and specificity of our MTX-nanostars.
SERS mapping results confirms that MTX-nanostars are distributed more or less uniformly
throughout the area of interest in the tumor tissue (Figure 7E). SERS mapping using
characteristic peak (Figure 7F) can reveal the localization and distribution of the MTXnanostars throughout the anatomical location of the lung tumor tissue.
The biodistribution of MTX-nanostars was also confirmed by ex vivo organ inductively
coupled plasma mass spectrometry (ICP-MS) for 0.5 and 5 hours after injection of the
19
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nanostars. The results show that 5 hours after injection, MTX-nanostars are mainly
accumulated in the lung (tumor), with less accumulation in most of the other tissues and
major organs, especially in the heart, liver and kidney (Supporting Information Figure S4B).

Figure 7. In vivo FTIR and SERS detection of MTX-nanostars in a lung cancer mice
model (n=6 animals). (A) Bioluminescent imaging of C57BL/6 mice bearing human Calu-1
xenograft tumor, to serially assed lung tumor development in each mouse, with luciferase
activity as a measure for the tumor burden. (B) ATR-FTIR imaging of the lung tumor tissue
for mice treated with MTX-nanostars. Arrows represent tumoral clones in the lung. ATRFTIR imaging of the lung tumor tissue for mice treated with MTX-nanostars after 0.5 (C) and
5 hours (D) after administration. Scale bars, 200 µm. (E) SERS mapping image showing a
laser beam focusing on the anatomical location of the lung tumor tissue (400×400 μm) based
on intensity of the band at 1573 cm−1. (F) SERS spectra obtained from three different tumor
tissue sites (a, b and c). SERS spectra were measured at 785 nm excitation with 2-s signal
integration. The spectra were background subtracted and shifted for better visualization. The
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colors and letters of the spectra correspond to the colors in (E). The band at ~1300 cm−1 is a
characteristic band of the MTX-nanostars.

CONCLUSION
In summary, we propose a novel strategy based on plasmonic-tunable Raman/FTIR imaging
spectroscopy, to directly track the delivery and release of an anticancer drug (Mitoxantrone –
MTX) by gold nanostars in single living cells and in two mice models: drug accumulation in
the heart of healthy mice and in the tumor of lung cancer mice. Through the enhancement of
the Raman signals from MTX molecules by the plasmonic field of the nanoparticles, we could
simultaneously observe the anticancer drug scattering cellular imaging using the Raman
scattering molecular vibration signals from molecules in living cells and in vivo, through a
plasmonic-tunable Raman/FTIR imaging platform. This method proved to be extremely
effective in detecting drug accumulation in both healthy and cancer tissue, being able to
clearly individualize each tumoral clone in the lung, holding a great promise for application in
image-guided cancer chemotherapy.

METHODS
Synthesis of gold nanostars via seed mediated route using HEPES buffer. 50-100 μL of
10 nm citrate capped gold colloid (Sigma Aldrich, Germany) was added to 12.5 mL of 30 mM
HEPES (3-[4-(2-hydroxyethyl)piperazin-1-yl]propane-1-sulfonic acid, Lonza) buffer (pH 7.0)
cooled in ice bath with gentle stirring in a plastic container. NH4OH (Sigma Aldrich,
Germany) was added to the reaction mixture to a final concentration of 0.4 mM. Stirring
process was stopped before adding 2.5 mL of 1.0 mM gold(III) chloride hydrate solution
(HAuCl4×H2O, Sigma Aldrich, Germany). The mixture was kept in ice bath protected from
light until a color change was observed. The sample was stored immediately at 4°C protected
from light.
Functionalization of HEPES-buffered gold nanostar through conjugation with PEG and
Mitoxantrone. For the all functionalization steps and quantification assays of the nanostars
with the PEG, can be found in Supplementary information.
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Characterization of functionalized gold nanostars. The stability of the gold nanostars
solution was tested for up to one month in 4ºC according to proceed. 13 The diameter, Zeta
Potential and Surface Plasmon Resonance peaks of the zeta potentials of the nanostars with
and without MTX are depicted in Table 1.
Raman spectroscopy. Raman spectroscopy was performed with a HORIBA Jobin Yvon
HR800 spectrometer with 532 nm, 632 nm, and 785 nm diode laser as source according to
proceed. 13 Spectral data were collected using a 10× microscope objective over the range 4001800 cm−1 with a 10 sec integration time. The detector used was a 16-bit dynamic range
Peltier cooled CCD detector. Solutions were dropped onto CaF2 substrates and measured
immediately. For comparison, spectra of the probe molecule MTX alone were recorded from
1M aqueous solutions.
Cell culture. The human adenocarcinoma (Calu-1) were cultured in complete culture medium
of RPMI 1640 with L-Glutamine (Invitrogen, Ireland) supplemented with 10% (v/v) Fetal
Bovine Serum (Sigma Aldrich, Ireland) and 1% (v/v) 10000 U/ml Penicillin and 10000 U/ml
Streptomycin (Invitrogen, Ireland). Cells were maintained on flasks at 5% CO2, 95% relative
humidity and 37°C. For subculture 0.25% trypsin and 0.03% EDTA solution were rained to
remove the cell. Interval of cell passage were: every 6 to 8 days for all experimentation.
Cell viability assay. Nanostar and MTX-nanostars biocompatibility was evaluated in an
epithelial cell line (Calu-1) over period 6 to 72 hours. In the WST-1 assay, cells were seeded
on microplates at a concentration 4000 cell/well in 100µl culture medium containing GNPs.
Different concentration of gold nanoparticle was loaded in the microplates at concentrations
ranging from 0.0001-1 mg/mL. The cells were incubated for 6, 12, 24, 48 and 72 hours at
37°C and 5% CO2 after adding GNPS. A 10 µl/well cell proliferation reagent WST-1 was
mixture with cell medium and incubated for 4 h at 37°C and 5% CO2. The samples were
measured at the absorbance wavelength of 450 nm. A triplicate analysis was performed from
three independent experiments (n=3).
In vitro application of Raman Spectroscopy. Calcium Fluoride (CaF2) substrate was
immersed in virkon for a few hours or overnight before plating the cells. The substrate was
washed using sterilized water and placed in a small petri dish. Calu-1 cells were trypsinised
and counted. A sufficient amount (approximately 500 µL) of cells suspension was added to
cover the substrate. The dish was incubated in CO2 incubator for 3 hours. A fresh media (with
10% Fetal bovine serum, FBS) with nanostar was added to the 3 cm petro dish and the plates
at final concentration of 0.2 mg/mL MTX-nanostars were left to be incubated for a period of
1, 4, 8, 24, 48 and 72 hours. After the incubation period, the media in the dish is discarded and
washed away using Phosphate buffered saline (PBS buffer). 3 mL of PBS buffer was added
into the plate and the plate is ready to be measured using Raman spectroscopy.
Confocal microscopy imaging. Calu-1 cells were seeded at a density of 1×104 cells/cm2 and
treated with 0.2 mg/mL MTX-nanostars in 3 cm petro dish for 24, 48 and 72 hours. Samples
were then imaged by laser scanning microscopy (Carl Zeiss 510, at a 400× magnification).
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With each time points, four images per sample were captured to gain a representative
understanding of drug location in Calu-1 epithelial cells following MTX-nanostars exposure.
FTIR Instrumentation. Six different cell samples and tissue slides samples were seed on the
CaF2 crystal substrate to recording NIR spectra. NIR spectra were recorded with the Perkin
Elmer Spotlight 400N Universal Attenuated Total Reflectance (UATR) accessory of the
spectrometer. The spectral data were the result of 4 scans, with a spectral resolution of 8 cm-1.
Dynamic distribution of nanostar-MTX in mice. In order to better understand and predict
drug effects and toxicities, drug distribution in time and location were recorded to
complement pharmacokinetic data Briefly, MTX-nanostars (0.2 mL, 10 mg/kg) were injected
into mice through the vena caudalis after chloroform inhalation. NIR imaging system
equipped with a 765 nm laser as excitation source was employed to trace the distribution of
the nanostar-MTX. The background image of the mice was taken prior to the injection. Due to
a significant decrease in drug fluorescence after administration, a series of images were
collected at 1, 2, 3 and 5 minutes post-injection respectively. All animal experiments were
approved by the Institutional Animal Care and Use Committee of Shanghai Jiao Tong
University (NO.SYXK2007-0025). The background fluorescence that was measured before
injection was subtracted from the post injection fluorescence. In order to confirm the biodistribution of the nanostar in living mice, some major organs (heart, liver, spleen, lung,
kidney, intestine of the subject mice were excised at 5 min post-injection and detected by NIR
fluorescence imaging system.
Histology and immunolocalisation. After mice have been sacrificed and perfused with
sterile PBS, heart, aorta and skin located at the back of mice with highest fluorescent intensity
point under NIR imaging were snap-frozen in optimum cutting temperature compound
(Tissue-Tek®) and cut on a cryostat microtome. Frozen sections were stained for hematoxylin
and eosin using standard procedures. Stained tissue sections were then imaged by light
microscopy. For immunolocalisation, the tissues sections were stained with a green phalloidin
probe (Invitrogen) at a 1:40 dilution. Subsequently tissues were then imaged by ZEISS
Confocal scanning microscopy at laser line 488 nm and 514 nm.
In vivo SERS. MTX-nanostars (0.2 mL, 10 mg/kg) were injected into mice through the vena
caudalis. The lung cancer tissue was directly carried out Raman imaging, and the flat area in
the tissue was attractive candidate. Raman imaging was carried out in a LabRAM HR
Evolution spectrometer (Horiba Scientific,) with a computer-controlled x,y stage in a 5 μm
step size at 633 nm excitation, using a 10× objective with a detection range from 1000-1600
cm−1. The excitation intensity and accumulation time was 5 mW and 2 s, respectively.

23

BIOMATERIALS
ACKNOWLEDGEMENTS
This work has been supported by Science Foundation Ireland 11/PI/1108 and a Marie Curie
Intra European Fellowship, Grant Agreement n° PIEF-GA-2012-332462 within the project
“Gold nanoprisms (AuNPrs) for applications in Raman based lung cancer diagnosis”. This
work is also supported by the National Key Basic Research Program (973 Project)
(No.2015CB931802), National Natural Scientific Fund (No. 81225010), 863 Project of China
(2014AA020700), Shanghai Science and Technology Fund (No. 15DZ2252000).

REFERENCES
(1) Tong, S.; Fine, E. J.; Lin, Y.; Cradick, T. J.; Bao, G., Nanomedicine: Tiny Particles and
Machines Give Huge Gains. Annals of biomedical engineering 2014, 42 (2), 243-259.
(2) Liang, X. J.; Chen, C.; Zhao, Y.; Wang, P. C., Circumventing Tumor Resistance to
Chemotherapy by Nanotechnology. Methods in molecular biology 2010, 596, 467-488.
(3) Sperling, R. A.; Rivera, G. P.; Zhang, F.; Zanella, M.; Parak, W. J., Biological
Applications of Gold Nanoparticles. Chem.Soc.Rev. 2008, 37 (9), 1896-1908.
(4) Giljohann, D. A.; Seferos, D. S.; Daniel, W. L.; Massich, M. D.; Patel, P. C.; Mirkin, C.
A., Gold Nanoparticles for Biology and Medicine. Angew.Chem.Int.Ed Engl. 2010, 49 (19),
3280-3294.
(5) Bao, C. C.; Conde, J.; Polo, E.; del Pino, P.; Moros, M.; Baptista, P. V.; Grazu, V.; Cui, D.
X.; de la Fuente, J. M., A Promising Road with Challenges: Where Are Gold Nanoparticles in
Translational Research? Nanomedicine 2014, 9 (15), 2353-2370.
(6) Conde, J.; Dias, J. T.; Grazu, V.; Moros, M.; Baptista, P. V.; de la Fuente, J. M.,
Revisiting 30 Years of Biofunctionalization and Surface Chemistry of Inorganic
Nanoparticles for Nanomedicine. Front Chem. 2014, 2, 48.
(7) Murphy, C. J.; Gole, A. M.; Stone, J. W.; Sisco, P. N.; Alkilany, A. M.; Goldsmith, E. C.;
Baxter, S. C., Gold Nanoparticles in Biology: Beyond Toxicity to Cellular Imaging.
Acc.Chem.Res. 2008, 41 (12), 1721-1730.
(8) Conde, J.; Tian, F.; Hernandez, Y.; Bao, C.; Cui, D.; Janssen, K. P.; Ibarra, M. R.;
Baptista, P. V.; Stoeger, T.; de la Fuente, J. M., In Vivo Tumor Targeting Via Nanoparticle-

24

BIOMATERIALS
Mediated Therapeutic Sirna Coupled to Inflammatory Response in Lung Cancer Mouse
Models. Biomaterials 2013, 34 (31), 7744-7753.
(9) Conde, J.; Oliva, N.; Artzi, N., Implantable Hydrogel Embedded Dark-Gold Nanoswitch
as a Theranostic Probe to Sense and Overcome Cancer Multidrug Resistance. Proc Natl Acad
Sci U S A 2015, 112 (11), E1278-1287.
(10) Harmsen, S.; Huang, R.; Wall, M. A.; Karabeber, H.; Samii, J. M.; Spaliviero, M.;
White, J. R.; Monette, S.; O'Connor, R.; Pitter, K. L.; Sastra, S. A.; Saborowski, M.; Holland,
E. C.; Singer, S.; Olive, K. P.; Lowe, S. W.; Blasberg, R. G.; Kircher, M. F., SurfaceEnhanced Resonance Raman Scattering Nanostars for High-Precision Cancer Imaging. Sci
Transl Med 2015, 7 (271), 271ra277.
(11) Conde, J.; Ambrosone, A.; Sanz, V.; Hernandez, Y.; Marchesano, V.; Tian, F. R.; Child,
H.; Berry, C. C.; Ibarra, M. R.; Baptista, P. V.; Tortiglione, C.; de la Fuente, J. M., Design of
Multifunctional Gold Nanoparticles for in Vitro and in Vivo Gene Silencing. Acs Nano 2012,
6 (9), 8316-8324.
(12) Patel, K. J.; Tredan, O.; Tannock, I. F., Distribution of the Anticancer Drugs
Doxorubicin, Mitoxantrone and Topotecan in Tumors and Normal Tissues. Cancer
chemotherapy and pharmacology 2013, 72 (1), 127-138.
(13) Tian, F.; Bonnier, F.; Casey, A.; Shanahan, A. E.; Byrne, H. J., Surface Enhanced Raman
Scattering with Gold Nanoparticles: Effect of Particle Shape. Anal Methods-Uk 2014, 6 (22),
9116-9123.
(14) Panchapakesan, B.; Book-Newell, B.; Sethu, P.; Rao, M.; Irudayaraj, J., Gold
Nanoprobes for Theranostics. Nanomedicine (Lond) 2011, 6 (10), 1787-1811.
(15) Niidome, T.; Yamagata, M.; Okamoto, Y.; Akiyama, Y.; Takahashi, H.; Kawano, T.;
Katayama, Y.; Niidome, Y., Peg-Modified Gold Nanorods with a Stealth Character for in
Vivo Applications. Journal of controlled release : official journal of the Controlled Release
Society 2006, 114 (3), 343-347.
(16) Hirsch, L. R.; Stafford, R. J.; Bankson, J. A.; Sershen, S. R.; Rivera, B.; Price, R. E.;
Hazle, J. D.; Halas, N. J.; West, J. L., Nanoshell-Mediated near-Infrared Thermal Therapy of
Tumors under Magnetic Resonance Guidance. Proc Natl Acad Sci U S A 2003, 100 (23),
13549-13554.
(17) Rodriguez-Oliveros, R.; Sanchez-Gil, J. A., Gold Nanostars as Thermoplasmonic
Nanoparticles for Optical Heating. Opt Express 2012, 20 (1), 621-626.

25

BIOMATERIALS
(18) Rodriguez-Lorenzo, L.; Krpetic, Z.; Barbosa, S.; Alvarez-Puebla, R. A.; Liz-Marzan, L.
M.; Prior, I. A.; Brust, M., Intracellular Mapping with Sers-Encoded Gold Nanostars.
Integrative biology : quantitative biosciences from nano to macro 2011, 3 (9), 922-926.
(19) Li, M.; Kang, J. W.; Dasari, R. R.; Barman, I., Shedding Light on the ExtinctionEnhancement Duality in Gold Nanostar-Enhanced Raman Spectroscopy. Angew Chem Int Ed
Engl 2014, 53 (51), 14115-14119.
(20) Dam, D. H.; Culver, K. S.; Kandela, I.; Lee, R. C.; Chandra, K.; Lee, H.; Mantis, C.;
Ugolkov, A.; Mazar, A. P.; Odom, T. W., Biodistribution and in Vivo Toxicity of AptamerLoaded Gold Nanostars. Nanomedicine 2015, 11 (3), 671-679.
(21) Vo-Dinh, T.; Fales, A. M.; Griffin, G. D.; Khoury, C. G.; Liu, Y.; Ngo, H.; Norton, S. J.;
Register, J. K.; Wang, H. N.; Yuan, H., Plasmonic Nanoprobes: From Chemical Sensing to
Medical Diagnostics and Therapy. Nanoscale 2013, 5 (21), 10127-10140.
(22) Liu, Y.; Yuan, H.; Kersey, F. R.; Register, J. K.; Parrott, M. C.; Vo-Dinh, T., Plasmonic
Gold Nanostars for Multi-Modality Sensing and Diagnostics. Sensors (Basel) 2015, 15 (2),
3706-3720.
(23) Esenturk, E. N.; Walker, A. R. H., Surface-Enhanced Raman Scattering Spectroscopy
Via Gold Nanostars. J Raman Spectrosc 2009, 40 (1), 86-91.
(24) Bi, S.; Jia, X.; Ye, J.; Dong, Y., Linear Light-Scattering of Gold Nanostars for Versatile
Biosensing of Nucleic Acids and Proteins Using Exonuclease Iii as Biocatalyst to Signal
Amplification. Biosens Bioelectron 2015, 71, 427-433.
(25) Liu, Y. et al. A Plasmonic Gold Nanostar Theranostic Probe for In Vivo Tumor Imaging
and Photothermal Therapy. Theranostics. 2015, 5, 946–960.
(26) Yuan, H.; Khoury, C. G.; Hwang, H.; Wilson, C. M.; Grant, G. A.; Vo-Dinh, T., Gold
Nanostars: Surfactant-Free Synthesis, 3d Modelling, and Two-Photon Photoluminescence
Imaging. Nanotechnology 2012, 23 (7), 075102.
(27) Khlebtsov, N.; Dykman, L., Biodistribution and Toxicity of Engineered Gold
Nanoparticles: A Review of in Vitro and in Vivo Studies. Chemical Society reviews 2011, 40
(3), 1647-1671.
(28) De Jong, W. H.; Borm, P. J., Drug Delivery and Nanoparticles:Applications and Hazards.
Int J Nanomedicine 2008, 3 (2), 133-149.
(29) Xie, J. P.; Lee, J. Y.; Wang, D. I. C., Seedless, Surfactantless, High-Yield Synthesis of
Branched Gold Nanocrystals in Hepes Buffer Solution. Chemistry of Materials 2007, 19 (11),
2823-2830.

26

BIOMATERIALS
(30) Regev, R.; Yeheskely-Hayon, D.; Katzir, H.; Eytan G.D., Transport of anthracyclines
and mitoxantrone across membranes by a flip-flop mechanism Biochem. Pharmacol. 2005,
70, 161-169.
(31) Homolya, L.; Orbán, T.I.; Csanády, L.; Sarkadi, B., Mitoxantrone is expelled by the
ABCG2 multidrug transporter directly from the plasma membrane. Biochim Biophys Acta.
2011, 1808(1), 154-163.
(32) Shenkenberg, T.D.; Von Hoff, D.D., Mitoxantrone: a new anticancer drug with
significant clinical activity. Ann Intern Med. 1986, 105(1), 67-81.
(33) Jin, R.; Cao, Y.; Mirkin, C. A.; Kelly, K. L.; Schatz, G. C.; Zheng, J. G., Photoinduced
Conversion of Silver Nanospheres to Nanoprisms. Science 2001, 294 (5548), 1901-1903.
(34) Millstone, J. E.; Hurst, S. J.; Metraux, G. S.; Cutler, J. I.; Mirkin, C. A., Colloidal Gold
and Silver Triangular Nanoprisms. Small 2009, 5 (6), 646-664.
(35) Mikoliunaite, L.; Rodriguez, R. D.; Sheremet, E.; Kolchuzhin, V.; Mehner, J.;
Ramanavicius, A.; Zahn, D. R., The Substrate Matters in the Raman Spectroscopy Analysis of
Cells. Sci Rep 2015, 5, 13150.
(36) Ganbold, E. O.; Yoon, J.; Kim, D.; Joo, S. W., Nonidentical Intracellular Drug Release
Rates in Raman and Fluorescence Spectroscopic Determination. Physical chemistry chemical
physics : PCCP 2015, 17 (5), 3019-3023.
(37) Chen, H.; Zhang, X.; Dai, S.; Ma, Y.; Cui, S.; Achilefu, S.; Gu, Y., Multifunctional Gold
Nanostar Conjugates for Tumor Imaging and Combined Photothermal and Chemo-Therapy.
Theranostics 2013, 3 (9), 633-649.
(38) Ostrowska, K.M., et al. Correlation of p16INK4A expression and HPV copy number
with cellular FTIR spectroscopic signatures of cervical cancer cells. The Analyst, 2011, 136,
1365-1373.
(39) Kreyling, W. G.; Semmler-Behnke, M.; Seitz, J.; Scymczak, W.; Wenk, A.; Mayer, P.;
Takenaka, S.; Oberdorster, G., Size Dependence of the Translocation of Inhaled Iridium and
Carbon Nanoparticle Aggregates from the Lung of Rats to the Blood and Secondary Target
Organs. Inhal Toxicol 2009, 21 Suppl 1, 55-60.
(40) Nedosekin, D. A.; Shashkov, E. V.; Galanzha, E. I.; Hennings, L.; Zharov, V. P.,
Photothermal Multispectral Image Cytometry for Quantitative Histology of Nanoparticles and
Micrometastasis in Intact, Stained and Selectively Burned Tissues. Cytometry. Part A : the
journal of the International Society for Analytical Cytology 2010, 77 (11), 1049-1058.

27

BIOMATERIALS
(41) Gong, K.; Zhang, Z.; Sun, X.; Zhang, X.; Li, A.; Yan, J.; Luo, Q.; Gao, Y.; Feng, Y., The
Nonspecific Anti-Inflammatory Therapy with Methotrexate for Patients with Chronic Heart
Failure. Am Heart J 2006, 151 (1), 62-68.

28

